In a first renal outcome trial of its kind, the SGLT2 inhibitor showed favorable outcomes in the most advanced stages of CKD.

Compass Pathways' latest update reveals extended trial timelines, staff cuts, and financial concerns, raising questions about ...

In its presentation at ObesityWeek 2024 meeting in Texas, the multinational drug company AstraZeneca (NASDAQ:AZN) revealed ...

Shuttle Pharmaceuticals (NASDAQ: SHPH), a rising force in cancer treatment innovation, has experienced a notable boost in its ...

Long-term treatment with the cell therapy NurOwn was found to significantly extend survival for ALS patients compared with ...

The patient died four months after BEAM-101 infusion “due to respiratory failure that was determined by the investigator to ...

ESSA Pharma has terminated the Phase II clinical trial of masofaniten, a new prostate cancer treatment. Masofaniten, previously known as EPI-7386, is an investigational oral, small-molecule androgen ...

Anavex announced new data from their phase 2b/3 Alzheimer's trial, which was presented at the CTAD 2024 conference. Read why ...

Three phase 3 trials of combinations including datopotamab deruxtecan for the treatment of non–small cell lung cancer are beginning.

Akeso begins patient enrollment in phase 3 trial of ivonescimab combination as first-line therapy for biliary tract tumours, compared to durvalumab: China Monday, November 4, 2024 ...

Topline supports moving to Phase 3 trial and shows potential to develop GV1001 as the world's first PSP treatment SEOUL, ...

PAR made substantial progress in its Phase 3 clinical trial preparations for the treatment of knee osteoarthritis (OA) with ...